Bank of New York Mellon’s vTv Therapeutics VTVT Stock Holding History

Bank of New York Mellon’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-571	Closed	-$64K	–	4474
2021 Q1	$64K	Sell	571 -15	-3%	-$1.47K	﹤0.01%	4224
2020 Q4	$43K	Sell	586 -31	-5%	-$2.38K	﹤0.01%	4162
2020 Q3	$44K	Buy	617 +15	+2%	+$1.32K	﹤0.01%	4032
2020 Q2	$55K	Buy	+602	New	+$59.4K	﹤0.01%	3973
2018 Q2	–	Sell	-549	Closed	-$90K	–	4312
2018 Q1	$90K	Hold	549	–	–	﹤0.01%	4079
2017 Q4	$132K	Hold	549	–	–	﹤0.01%	4030
2017 Q3	$131K	Sell	549 -2	-0.4%	-$399	﹤0.01%	3954
2017 Q2	$110K	Sell	551 -19	-3%	-$3.96K	﹤0.01%	4009
2017 Q1	$149K	Buy	570 +33	+6%	+$7.53K	﹤0.01%	3947
2016 Q4	$104K	Buy	537 +5	+0.9%	+$1.15K	﹤0.01%	4026
2016 Q3	$153K	Buy	532 +38	+8%	+$9.15K	﹤0.01%	3954
2016 Q2	$115K	Hold	494	–	–	﹤0.01%	4029
2016 Q1	$102K	Buy	494 +18	+4%	+$4.48K	﹤0.01%	3955
2015 Q4	$130K	Buy	476 +43	+10%	+$12.1K	﹤0.01%	3996
2015 Q3	$113K	Buy	+433	New	+$151K	﹤0.01%	4076

Other funds holding VTVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WAG

Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of New York Mellon's VTVT Position: Q2 2021 in Review

Bank of New York Mellon sold out of vTv Therapeutics (VTVT) in Q2 2021, closing a stake of 571 shares — an estimated $64K sold.

Bank of New York Mellon first reported a position in VTVT in Q3 2015 and held it in 15 quarters. The position peaked at $153K in Q3 2016. 42 funds tracked by Wall St. Rank hold VTVT as of Q2 2021.

Bank of New York Mellon reported no remaining vTv Therapeutics position as of Q2 2021 after selling out during the quarter.
Bank of New York Mellon sold 571 vTv Therapeutics shares in Q2 2021, an estimated $64K.
Bank of New York Mellon first reported a position in vTv Therapeutics in Q3 2015 and held it in 15 quarters.
Bank of New York Mellon's vTv Therapeutics position peaked at $153K in Q3 2016.
42 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2021.

Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.